Clinical Trial

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this study is to evaluate the safety and effi cacy of CD19 CAR T cells in the treatment of Refractory Autoimmune Diseases.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-11-12; most recent amendment 2026-03-06.
Status change: Not Yet Recruiting → Recruiting 2024-12-08
Trial Details
NCT Number NCT06688799
Lead Sponsor Beijing GoBroad Hospital
Conditions Autoimmune Diseases
Enrollment 18 participants
Start Date 2024-11-23
Primary Completion 2026-03 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-10